JECURE THERAPEUTICS
Jecure Therapeutics is focused on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis.
JECURE THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Health Diagnostics Therapeutics
Founded:
2016-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.jecuretx.com
Total Employee:
11+
Status:
Active
Contact:
(888) 888-8888
Email Addresses:
[email protected]
Total Funding:
20 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Domain Not Resolving
Similar Organizations
ACEA Therapeutics
ACEA Therapeutics develops and delivers innovative treatments to improve the lives of patients with life-threatening diseases.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Founder
Investors List
Versant Ventures
Versant Ventures investment in Series A - Jecure Therapeutics
Official Site Inspections
http://www.jecuretx.com
- Host name: 143.244.163.156
- IP address: 143.244.163.156
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Jecure Therapeutics"
Jecure Therapeutics - Crunchbase Company Profile & Funding
Organization. Jecure Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone โฆSee details»
Jecure Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Www.jecuretx.com. Startups | Subsidiary Company | 2016 | California, United States | 10-50 | www.jecuretx.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational โฆSee details»
Jecure Therapeutics - LinkedIn
Jecure Therapeutics is focused on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis.See details»
Jecure Therapeutics Overview | SignalHire Company Profile
Organization Website. jecuretx.com . Jecure Therapeutics industries. Biotech Headquarters Location. 4757 Nexus Center Drive, San Diego, CA, 92121 US. Jecure Therapeutics โฆSee details»
Jecure Therapeutics Company Overview, Contact Details
Jecuretx hired Gretchen Bain as Vice President of Biology on Dec 14th '17. Jecure Therapeutics, a biotechnology company with novel drug discovery programs targeting non-alcoholic โฆSee details»
Versant Ventures Launches Jecure
Investor Versant Ventures. For more information, please visit www.jecuretx.com. About Versant Ventures Versant Ventures is a leading global healthcare investment firm committed to helping โฆSee details»
Jecure Therapeutics - PitchBook
Jecure Therapeutics General Information Description. Operator of a biotechnology company intended to provide novel drug discovery programs targeting serious inflammatory diseases โฆSee details»
Jecure Therapeutics, Inc. - VentureRadar
Jecure Therapeutics' objective is to identify novel drugs for the treatment of fatty liver disease and liver fibrosis. ... Find out more about Jecure Therapeutics, Inc., Life Sciences.See details»
Jecureโs Competitors, Revenue, Number of Employees, Funding
Jecureโs Profile, Revenue and Employees. Jecure discovers and develops small-molecule therapeutics for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Jecureโs โฆSee details»
Jecure Therapeutics, Inc. | CipherBio
Explore Jecure Therapeutics, Inc.'s investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Genentech Acquires Jecure Therapeutics - Business Wire
Nov 27, 2018 For more information, please visit www.jecuretx.com. Contacts. For Genentech or Jecure: Susan Willson 650-467-6800 [email protected]. For Versant: Steve Edelson 415 โฆSee details»
Jecure Therapeutics, Inc. (Jecure Therapeutics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธ โฆ
The NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome is a multiprotein complex and component of the innate immune system that is activated by exogenous and โฆSee details»
Genentech Acquires Jecure Therapeutics - MarketScreener
Nov 27, 2018 Jecureโs lead program has identified small molecule inhibitors of the NLRP3 inflammasome, a novel target and pro-inflammatory driver of NASH. Jecure is backed by top โฆSee details»
Genentech Acquires Jecure Therapeutics | Financial Post
Nov 27, 2018 SAN DIEGO โ Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases, today announced a definitโฆSee details»
Jecure Therapeutics | Portfolio | Versant Ventures
Jecure is a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases.See details»
Genentech Acquires Jecure Therapeutics - BioSpace
Nov 27, 2018 SAN DIEGO--(BUSINESS WIRE)-- Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases, today โฆSee details»
Versant Ventures Launches Jecure Therapeutics - Business Wire
Feb 15, 2017 Versant Ventures today announced the debut of Jecure Therapeutics, a biotechnology company with a proprietary liver disease platform that has generateSee details»
Jecure Therapeutics Strengthens Management Team - BioSpace
Dec 14, 2017 SAN DIEGO, Calif.--(BUSINESS WIRE)-- Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting non-alcoholic โฆSee details»
Jecure Therapeutics Strengthens Management Team - Business Wire
Dec 14, 2017 SAN DIEGO, Calif.--(BUSINESS WIRE)--Jecure Therapeutics, a biotechnology company with novel drug discovery programs targeting non-alcoholic steatohepatitis (NASH) โฆSee details»